A shorter radiation course improved quality of life among men with intermediate-risk, localized prostate cancer, according to results of a randomized phase 3 trial.

For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a ...

A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation ...

The addition of neoadjuvant Lutetium-177 (Lu-177) therapy to metastasis-directed stereotactic body radiation therapy (SBRT) more than doubled progression-free survival (PFS) in men with ...

SAN FRANCISCO -- For patients with recurrent prostate cancer, those with a certain subtype had clinically meaningful benefits when apalutamide (Erleada) was added to salvage radiotherapy after radical ...

Until about 15 years ago, most men diagnosed with prostate cancer — no matter how aggressive — underwent surgery or radiation. But that’s changed. Research has shown that patients often have similar ...

SAN FRANCISCO — A genomic test can identify patients with recurrent prostate cancer who are most likely to benefit from adding hormone therapy to secondary radiotherapy, according to findings ...

A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery - the ...

TOLEDO, Ohio — Brian Byrd spent decades running towards danger as chief of Toledo Fire & Rescue Department. But shortly after retirement, the longtime first responder faced an unexpected emergency of ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a ...